Compare
Elicio Therapeutics, Inc. vs CASI Pharmaceuticals, Inc. vs Integrated Biopharma Inc vs Onconetix, Inc.
| Latest fiscal year | Elicio Therapeutics, Inc. ELTX | CASI Pharmaceuticals, Inc. CASIF | Integrated Biopharma Inc INBP | Onconetix, Inc. ONCO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $20.71M | $43.87M | $815.4K |
| Revenue growth (YoY) | n/a | -27.4% | -19.3% | -67.7% |
| Gross margin | n/a | 48.6% | 1.8% | 77.6% |
| Operating margin | n/a | -217.3% | -6.2% | n/m |
| Net margin | n/a | -232.0% | -6.5% | n/m |
| Net income | -$39.57M | -$48.06M | -$2.84M | -$14.03M |
| EPS (Diluted) | -$2.58 | -$2.59 | -$0.09 | -$16.56 |
| Operating cash flow | -$36.95M | -$20.75M | $1.24M | -$9.68M |
| Free cash flow | -$36.97M | -$20.77M | $895.0K | n/a |
| Cash & equivalents | $18.56M | $5.63M | $4.47M | n/a |
| Total assets | $25.86M | $25.65M | $25.34M | $24.93M |
| Total liabilities | $24.23M | $62.93M | $7.67M | $9.16M |
| Shareholders' equity | $1.64M | -$37.28M | $17.67M | $15.76M |
| Return on year-end equity | n/m | n/a | -16.1% | -89.0% |
| Shares outstanding | 17.80M | 20.56M | 31.06M | 1.56M |
Revenue, most recent five fiscal years
| Fiscal year | Elicio Therapeutics, Inc. | CASI Pharmaceuticals, Inc. | Integrated Biopharma Inc | Onconetix, Inc. |
|---|---|---|---|---|
| Latest | $2.30M Ended 2022-12-31 | $20.71M Ended 2025-12-31 | $43.87M Ended 2026-06-30 | $815.4K Ended 2025-12-31 |
| 1 year earlier | $28.31M Ended 2021-12-31 | $28.54M Ended 2024-12-31 | $54.35M Ended 2025-06-30 | $2.52M Ended 2024-12-31 |
| 2 years earlier | $2.88M Ended 2020-12-31 | $33.88M Ended 2023-12-31 | $50.32M Ended 2024-06-30 | $58.5K Ended 2023-12-31 |
| 3 years earlier | n/a | $43.11M Ended 2022-12-31 | $50.67M Ended 2023-06-30 | n/a |
| 4 years earlier | n/a | $30.17M Ended 2021-12-31 | $56.25M Ended 2022-06-30 | n/a |